Lucy Lu - Net Worth and Insider Trading

Lucy Lu Net Worth

The estimated net worth of Lucy Lu is at least $6,338 dollars as of 2024-11-13. Lucy Lu is the Director of Veru Inc and owns about 9,800 shares of Veru Inc (VERU) stock worth over $6,338. Details can be seen in Lucy Lu's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Lucy Lu has not made any transactions after 2021-08-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Lucy Lu

Lucy Lu Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Lucy Lu owns 3 companies in total, including Avenue Therapeutics Inc (ATXI) , Veru Inc (VERU) , and Fortress Biotech Inc (FBIO) .

Click here to see the complete history of Lucy Lu’s form 4 insider trades.

Insider Ownership Summary of Lucy Lu

Ticker	Comapny	Transaction Date	Type of Owner
ATXI	Avenue Therapeutics Inc	2020-02-12	director & President & CEO
VERU	Veru Inc	2021-08-17	director
FBIO	Fortress Biotech Inc	2022-12-14	director

Lucy Lu Latest Holdings Summary

Lucy Lu currently owns a total of 1 stock. Lucy Lu owns 9,800 shares of Veru Inc (VERU) as of August 17, 2021, with a value of $6,338.

Latest Holdings of Lucy Lu

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
VERU	Veru Inc	2021-08-17	9,800	0.65	6,338

Holding Weightings of Lucy Lu

Lucy Lu Form 4 Trading Tracker

According to the SEC Form 4 filings, Lucy Lu has made a total of 1 transactions in Veru Inc (VERU) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Veru Inc is the acquisition of 4,800 shares on August 17, 2021, which cost Lucy Lu around $32,544.

Insider Trading History of Lucy Lu

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Lucy Lu Trading Performance

GuruFocus tracks the stock performance after each of Lucy Lu's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Lucy Lu is 33.47%. GuruFocus also compares Lucy Lu's trading performance to market benchmark return within the same time period. The performance of stocks bought by Lucy Lu within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Lucy Lu's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Lucy Lu

Average Return

Average return per transaction

Outperforming Transactions

2 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	27.2
Relative Return to S&P 500(%)	26.59

Lucy Lu Ownership Network

Ownership Network List of Lucy Lu

No Data

Ownership Network Relation of Lucy Lu

Lucy Lu Owned Company Details

What does Avenue Therapeutics Inc do?

Who are the key executives at Avenue Therapeutics Inc?

Lucy Lu is the director & President & CEO of Avenue Therapeutics Inc. Other key executives at Avenue Therapeutics Inc include 10 percent owner Fortress Biotech, Inc. , 10 percent owner Invagen Pharmaceuticals, Inc. , and Chief Executive Officer Alexandra Maclean .

Avenue Therapeutics Inc (ATXI) Insider Trades Summary

Over the past 18 months, Lucy Lu made no insider transaction in Avenue Therapeutics Inc (ATXI). Other recent insider transactions involving Avenue Therapeutics Inc (ATXI) include a net purchase of 439 shares made by Jay D Kranzler , a net sale of 617,000 shares made by , and a net purchase of 418,410 shares made by Fortress Biotech, Inc. .

In summary, during the past 3 months, insiders sold 61 shares of Avenue Therapeutics Inc (ATXI) in total and bought 500 shares, with a net purchase of 439 shares. During the past 18 months, 8,288 shares of Avenue Therapeutics Inc (ATXI) were sold and 10,728 shares were bought by its insiders, resulting in a net purchase of 2,440 shares.

Avenue Therapeutics Inc (ATXI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avenue Therapeutics Inc Insider Transactions

No Available Data

What does Veru Inc do?

Who are the key executives at Veru Inc?

Lucy Lu is the director of Veru Inc. Other key executives at Veru Inc include director & 10 percent owner Harry Fisch , director & 10 percent owner & President and CEO Mitchell Shuster Steiner , and Chief Scientific Officer K Gary Barnette .

Veru Inc (VERU) Insider Trades Summary

Over the past 18 months, Lucy Lu made no insider transaction in Veru Inc (VERU). Other recent insider transactions involving Veru Inc (VERU) include a net sale of 242,058 shares made by Mitchell Shuster Steiner , a net purchase of 10,711 shares made by Harry Fisch , and a net purchase of 5,000 shares made by K Gary Barnette .

In summary, during the past 3 months, insiders sold 0 shares of Veru Inc (VERU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 242,058 shares of Veru Inc (VERU) were sold and 15,711 shares were bought by its insiders, resulting in a net sale of 226,347 shares.

Veru Inc (VERU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Veru Inc Insider Transactions

No Available Data

What does Fortress Biotech Inc do?

Who are the key executives at Fortress Biotech Inc?

Lucy Lu is the director of Fortress Biotech Inc. Other key executives at Fortress Biotech Inc include director & 10 percent owner & PRESIDENT & CEO & CHAIRMAN Rosenwald Lindsay A Md , Chief Financial Officer David Jin , and Chief Financial Officer Robyn Hunter .

Fortress Biotech Inc (FBIO) Insider Trades Summary

Over the past 18 months, Lucy Lu made no insider transaction in Fortress Biotech Inc (FBIO). Other recent insider transactions involving Fortress Biotech Inc (FBIO) include a net purchase of 2,510,874 shares made by Rosenwald Lindsay A Md , a net purchase of 147,058 shares made by Michael S Weiss , and a net sale of 10,000 shares made by Dov Klein .

In summary, during the past 3 months, insiders sold 0 shares of Fortress Biotech Inc (FBIO) in total and bought 763,359 shares, with a net purchase of 763,359 shares. During the past 18 months, 10,000 shares of Fortress Biotech Inc (FBIO) were sold and 2,564,599 shares were bought by its insiders, resulting in a net purchase of 2,554,599 shares.

Fortress Biotech Inc (FBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fortress Biotech Inc Insider Transactions

No Available Data

Lucy Lu Mailing Address

Above is the net worth, insider trading, and ownership report for Lucy Lu. You might contact Lucy Lu via mailing address: The Female Health Company, 4400 Biscayne Boulevard, Suite 888, Miami Fl 33137.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.